Graft vs Host Disease
179
21
33
95
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
36 trials with published results (20%)
Research Maturity
95 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.1%
18 terminated out of 179 trials
84.1%
-2.5% vs benchmark
15%
27 trials in Phase 3/4
38%
36 of 95 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 95 completed trials
Clinical Trials (179)
Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
Pediatric cGVHD Symptom Scale
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
High Dose Chemotherapy and Autologous Transplant for Breast Cancer
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
Optoacoustic Detection of Inflammation Using MSOT Device
A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT
Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Horizons Chronic Graft-Versus-Host-Disease Study
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Evaluation of the Impact of Reduced Immunosuppression